Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex

J Child Neurol. 2008 Oct;23(10):1238-9. doi: 10.1177/0883073808321764.

Abstract

The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.

Publication types

  • Case Reports

MeSH terms

  • Antibiotics, Antineoplastic / administration & dosage*
  • Brain / drug effects
  • Brain / pathology
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Brain Neoplasms / physiopathology
  • Dose-Response Relationship, Drug
  • Female
  • Glioma, Subependymal / drug therapy*
  • Glioma, Subependymal / pathology
  • Glioma, Subependymal / physiopathology
  • Humans
  • Magnetic Resonance Imaging
  • Sirolimus / administration & dosage*
  • Treatment Outcome
  • Tuberous Sclerosis / drug therapy*
  • Tuberous Sclerosis / pathology
  • Tuberous Sclerosis / physiopathology
  • Young Adult

Substances

  • Antibiotics, Antineoplastic
  • Sirolimus